Verteporfin
Antineovascularisation Agents
Sold as VISUDYNE
- Drug class
- Antineovascularisation Agents
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 3
Overview
Verteporfin is an active pharmaceutical ingredient in the Antineovascularisation Agents group (S01LA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 1 | May 29, 2026 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
| EU European Union | EMA | 1 | September 16, 2020 |
GBUnited Kingdom· MHRA
1 product
Uses
Visudyne/Verteporfin is indicated for the treatment of - adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or - adults with subfoveal choroidal neovascularisation secondary to pathological myopia.
How to take
CACanada· Health Canada
1 product
Uses
AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ......................................................................................................... 3 WARNINGS AND PRECAUTIONS .......................................................................................
4 ADVERSE REACTIONS ......................................................................................................... 8 DRUG INTERACTIONS .......................................................................................................
15 DOSAGE AND ADMINISTRATION ................................................................................... 16 OVERDOSAGE ......................................................................................................................
19 ACTION AND CLINICAL PHARMACOLOGY .................................................................. 19 STORAGE AND STABILITY ............................................................................................... 20 SPECIAL HANDLING INSTRUCTIONS .............................................................................
EUEuropean Union· EMA
1 product
Uses
Visudyne is indicated for the treatment of - adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or - adults with subfoveal choroidal neovascularisation secondary to pathological myopia.
How to take
Drug interactions
Known interactions involving Verteporfin. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 248. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB450430099 · revised May 29, 2026
- [2]Health Canada (DPD) · 02242367 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/000305 · revised September 16, 2020
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.